Purpose: To compare the variance in manifest refraction spherical equivalent (MRSE) after photorefractive keratectomy (PRK) with mitomycin-C (MMC), PRK without MMC, and laser in situ keratomileusis (LASIK) for the treatment of myopic astigmatism.
Setting: Jules Stein Eye Institute, University of California, Los Angeles, Los Angeles, California, USA.
Design: Retrospective case series.
Methods: Patients were classified into 3 groups of preoperative refraction-matched eyes as follows: PRK with MMC 0.02%, PRK without MMC, and LASIK. The preoperative and postoperative MRSE, preoperative corrected distance visual acuity, and postoperative uncorrected distance visual acuity (UDVA) were analyzed.
Results: Each group comprised 30 eyes. Follow-up was at least 6 months in the LASIK group and 12 months in the 2 PRK groups. There were no statistically significant differences in the mean preoperative MRSE (P=.95) or postoperative MRSE (P=.06) between the 3 groups. The mean postoperative MRSE was -0.07 diopter (D) ± 0.47 (SD), -0.14 ± 0.26 D, and 0.02 ± 0.25 D in the PRK with MMC 0.02% group, PRK without MMC group, and LASIK group, respectively. The variance in the postoperative MRSE in the PRK with MMC 0.02% group was significantly higher than that in the PRK without MMC group (P=.002) and in the LASIK group (P=.001). There was no statistically significant difference in the mean postoperative UDVA between the 3 groups (P=.47).
Conclusions: Refractive outcomes after PRK for myopia were more variable when MMC 0.02% was used. This should be weighed against the advantage of intraoperative MMC use in reducing haze after PRK.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jcrs.2014.02.048 | DOI Listing |
Purpose: To compare haze and refractive outcomes in patients undergoing combined accelerated corneal cross-linking (A-CXL) and selective wavefront-guided transepithelial photorefractive keratectomy (WG-transPRK) without mitomycin C (MMC) versus those undergoing A-CXL.
Methods: This prospective study analyzed 95 eyes (86 patients) with progressive keratoconus from October 2018 to October 2022. The first group underwent CXL combined with corneal or ocular WG-transPRK (CXL+PRK, n = 52), targeting higher order aberrations (HOAs).
Turk J Ophthalmol
June 2023
Wills Eye Hospital, Cornea Service, Philadelphia, USA.
Isolated from , mitomycin C (MMC) has various applications in the management of corneal and external disease due to its ability to modulate cellular proliferation. It has been employed in pterygium surgery, ocular surface neoplasia, and refractive surgery. Currently, there is no definite consensus on the treatment protocols for each of the aforementioned applications.
View Article and Find Full Text PDFJ Cataract Refract Surg
June 2023
Rio de Janeiro, Brazil.
A 51-year-old man was referred for refractive surgery evaluation. Spectacle dependence and poor visual quality in both eyes was his chief complaint. He cannot tolerate contact lenses.
View Article and Find Full Text PDFClin Ophthalmol
August 2022
Department of Ophthalmology, College of Medicine, Qassim University, Qassim, Kingdom of Saudi Arabia.
Purpose: This study investigated the effect of prophylactic mitomycin C (MMC) on corneal endothelium to inhibit corneal haze formation post transepithelial photorefractive keratectomy (T-PRK).
Methods: A total of 120 eyes of 60 patients with low, moderate, and high myopia were subjected to T-PRK with intraoperative application of MMC (0.02%) for 30-50s.
Ther Adv Ophthalmol
March 2022
Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences, University of Campania 'Luigi Vanvitelli', Naples, Italy.
Background: Corneal collagen cross-linking (CXL) is considered an effective procedure for slowing down or eliminating the progression of keratoconus. New techniques, in combination with CXL, have been proposed to stop the evolution of keratoconus and improve the visual function.
Objective: To evaluate the effectiveness of combined photorefractive keratectomy (PRK) with mitomycin-C (MMC) application and CXL in the management of grade 1-2 keratoconus over a 2-year follow-up.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!